Navigation Links
Targeted radiation therapy minimizes GI side effects for prostate cancer patients, Penn study shows
Date:10/26/2010

SAN DIEGO -- Prostate cancer patients who receive intensity modulated radiation therapy (IMRT) are less apt to suffer serious gastrointestinal complications following their treatment than those who receive three-dimensional conformal radiotherapy (CRT), according to new research from the University of Pennsylvania School of Medicine. The study, which will be presented Nov. 1 at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego, found that men who were treated with IMRT had fewer serious bowel complications, including painful rectal inflammation and bleeding (3.5 percent), compared to those who received CRT (4.5 percent).

"While radiotherapy is highly effective in treating prostate cancer, men may live with gastrointestinal, urinary and sexual side effects of treatment for many years. Minimizing these side effects and improving men's quality of life after prostate cancer treatment is incredibly important," says Justin Bekelman, MD, lead author of the study and an assistant professor of Radiation Oncology at the University of Pennsylvania School of Medicine. "Our study offers important evidence to patients and their doctors that IMRT is associated with fewer gastrointestinal problems after treatment."

CRT, the conventional form of radiation therapy, uses imaging studies including CT, MRI and PET scans to map the size, shape and location of tumors and the other organs in the area. IMRT is a more advanced version of CRT, offering a more targeted dose of radiation to the cancerous prostate gland. Since both forms of radiation pass all the way through the body after attacking their target, healthy tissue in the rectum and bladder may be damaged by the radiation beam, causing side effects during and after treatment. Though Medicare and private insurers typically cover both IMRT and CRT, little research has been conducted to show which treatment is associated with less side effects an important consideration for men choosing among the various treatment options for the disease, which include observation, radiation, surgery, chemotherapy and hormonal therapies.

Using a Medicare database of men across the United States, Bekelman's team studied 12,598 men 65 years and older who were diagnosed with non-metastatic prostate cancer between 2002 and 2004. The authors followed the patients through 2006 and identified complications that were serious enough to require invasive procedures (including surgeries) and/or hospitalization. The findings revealed that among men who received IMRT, 18.8 percent had serious bowel complications during the two years after their treatment, compared to 22.5 percent of men treated with CRT. (Since specifics about each patient's case could not be accounted for in the database, the authors note that some of the complications identified may have been caused by factors other than radiation treatment.) The researchers found no substantial difference in incidence of urinary or sexual side effects such as erectile dysfunction, but Bekelman notes that since the study was limited to complications involving invasive surgical procedures, it may not capture the true prevalence of sexual side effects following treatment, for which patients may have sought less invasive remedies.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Targeted delivery of losartan reduces liver inflammation and scarring
2. Gene-Targeted Cancer Fix Could Be a Breakthrough
3. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
4. Targeted agent blocked growth of deadly brain cancer in preclinical studies
5. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
6. New targeted therapy effective in treating advanced prostate cancer
7. Gene-Targeted Therapy Might Help Prevent Paralysis
8. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
9. Drug in new class of targeted therapies shows early promise against blood-related cancers
10. Women Smokers Targeted on World No Tobacco Day
11. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: